Participated · Series A · Apr 2022

Rona Therapeutics is a Shanghai-based clinical-stage platform company specializing in nucleic acid drug research and development, led by CEO and Founder Ms. Stella SHI. The company advances siRNA programs generated from a next-generation siRNA platform, focused on metabolic diseases and CNS degenerative disorders. Its lead program, RN0191—a PCSK9 siRNA—completed Phase 1 studies in Australia and China and is ready for Phase 2 development for hypercholesterolemia. RN0361 is expected to enter the clinic in 2024 Q2 for hypertriglyceridemia, and several additional programs are at IND-enabling stages for kidney disease, obesity, and cardiometabolic diseases. Rona is also working to expand its extra-hepatic delivery platform into the CNS and other tissues. The company completed a $35M Series A+ financing to fund global development of its metabolic siRNA pipeline and platform expansion. Rona Therapeutics operates an integrated platform dedicated to discovery, development and manufacturing of RNA therapeutics, with an emphasis on a proprietary delivery platform. Its RNA medicines are described as modular and programmable, designed to target metabolic, neurological and ophthalmology diseases via different delivery systems. The company intends to advance its proprietary delivery platform and its initial pipeline of therapeutics using the proceeds from the recent financing. Rona is building facilities to expand nucleic acid synthesis, oligonucleotide chemical modification, delivery capabilities, RNA biology and manufacturing capacity. Founded in 2021, the company is led by CEO and co-founder Stella SHI. The focus is on creating RNA medicines with more specific, stable and prolonged effects.

Participated · Series B · Feb 2021

Regor Therapeutics is a clinical-stage biotech focused on discovering and developing innovative, clinically differentiated medicines for oncology, immune disorders and metabolic diseases. The company leverages a proprietary CARD (Computer Accelerated Rational Discovery) Platform that integrates structural biology, computational chemistry, therapeutic biology, medicinal chemistry and clinical development. Regor emphasizes translating computational and structural insights into drug candidates for clinical advancement. The company was founded in July 2018 by Dr. Xiayang Qiu, who serves as CEO, and is based in Shanghai, China. Regor received an initial Series A strategic investment from Qilu Pharmaceutical Group. In February 2021 it closed a $90M Series B financing to advance its clinical-stage programs and discovery pipeline.